| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | 0.069 | 0.03 |
| mRNA | lapatinib | UHNBreast | pan-cancer | AAC | 0.6 | 0.03 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.075 | 0.03 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.06 | 0.04 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.083 | 0.05 |
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.06 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | 0.068 | 0.06 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.059 | 0.06 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | 0.056 | 0.06 |
| mRNA | paclitaxel | CTRPv2 | pan-cancer | AAC | 0.059 | 0.06 |